Collegium Pharmaceutical’s Upcoming Financial Reporting
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a well-regarded biopharmaceutical company, has announced its plan to release financial results for the fourth quarter and full-year 2024. This significant milestone is scheduled for the close of the market on February 27, 2025. After the announcement, the Company intends to conduct a live conference call and a webcast for investors to discuss the results and insights into their financial performance.
Conference Call Details
The conference call is open to all interested parties, and to participate, one can simply dial (877) 407-8037 if calling from the U.S., or (201) 689-8037 for international callers. Attendees should mention the "Collegium Pharmaceutical Q4 2024 Earnings Call" to access relevant discussions. Furthermore, an audio webcast will also be available on the Company’s investor section of their official website, making it easy for stakeholders to connect and engage with the earnings announcement.
Key Information About Collegium Pharmaceutical
Collegium is on a mission to enhance the lives of individuals grappling with serious medical conditions. The Company boasts a robust portfolio centered around responsible pain management medications, which is paramount in today's healthcare landscape. Recently, Collegium improved its portfolio by acquiring Jornay PM, a groundbreaking treatment for ADHD. This acquisition marks a pivotal step in establishing a footprint in the neuropsychiatry domain, which has substantial growth potential.
Strategic Growth Initiatives
The strategic vision of Collegium includes an expansion of its commercial portfolio, with Jornay PM positioned as the flagship growth engine. The Company emphasizes a disciplined approach to capital allocation, ensuring that each investment supports their overarching goal of enhancing patient outcomes. Based in Stoughton, Massachusetts, Collegium continues to evolve and adapt, investing in innovations that resonate with their mission.
Staying Connected with Stakeholders
To maintain a clear line of communication with investors and the media, Collegium has established dedicated contacts for inquiries. Danielle Jesse, the Director of Investor Relations, leads efforts to provide shareholders with timely updates regarding the Company's financial health and strategic goals. Meanwhile, for broader media engagements, Cheryl Wheeler serves as the head of corporate communications, ensuring that all public messaging aligns with Collegium's values and objectives.
Getting in Touch
Investors looking to communicate with Collegium can reach out via email at ir@collegiumpharma.com. For media-related inquiries, they may contact Cheryl Wheeler at communications@collegiumpharma.com. These lines of communication help ensure that interested parties receive accurate and up-to-date information, reflecting the Company’s commitment to transparency.
Frequently Asked Questions
What financial results will Collegium Pharmaceutical announce?
Collegium will report its financial results for the fourth quarter and full year of 2024 during a dedicated conference call.
How can I participate in the conference call?
You can join the conference call by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international callers.
What makes Collegium Pharmaceutical unique?
Collegium focuses on responsible pain management and has recently expanded into ADHD treatments, showcasing its commitment to diverse therapeutic areas.
Where is Collegium Pharmaceutical located?
The headquarters of Collegium Pharmaceutical is located in Stoughton, Massachusetts.
How can I contact Collegium for investor relations?
For investor-related questions, you can reach out to Danielle Jesse at ir@collegiumpharma.com.
